Dual-thermotherapy for parenchymal hepatic cells carcinoma

Objective: To study the efficacy and safety of transhepatic arterial dual-thermotherapy (DT) for parenchymal hepatic cells carcinoma. Methods: Fifty patients (mean age 55.5 years, DT group) with parenchymal hepatic cells carcinoma were treated with transhepatic arterial thermochemotherapy with warmed lipiodol (80 ℃) and warmed chemotherapehtic agents (50 ℃). Another 50 patients (mean age 54 years) were treated with ordinary transhepatic arterial chemomembolization (TACE) with the same chemotherapeutic drugs but without warming (TACE group). Results: The 1-, 2-, and 3-year survival rates were 77.6%, 53.1% and 46.1%, respectively, in TD group; and 54.4%, 24.2% and 16.1%, resectively, in TACE group; the difference was statistically significant(P0.05). The side-effect of the feeling of cauterization (cases/persistence time) in DT group was statistically significant compared with TACE group (P0.05), and the difference was not statistically significant about other side-effects. Conclusion: Tanshepatic arterial perfusion of warmed lipiodol (80 ℃) and chemotherapeutic agents (50 ℃), namely, dual-thermotherapy is a simple, safe and effective method for treating hepatic carcinoma with less complications than ordinary TACE.